A kinase inhibitor which is already authorised for myelofibrosis has now been approved by the Food and Drug Administration for polycythemia vera, another bone marrow disorder. The drug, Jakafi (ruxolitinib), was developed by Incyte Pharmaceuticals Inc and Novartis.
